"Paul Hunter, professor of medicine at the University of East Anglia, said other countries with active biotechnology industries will benefit, but the decision will still delay the development of new vaccines worldwide. "Progress will continue but not as quickly as otherwise. Lives will be lost that could have been saved had there been a vaccine," he told Times Higher Education."
"The U.S. Department of Health and Human Services said 22 projects by major pharmaceutical companies, including Pfizer and Moderna, will be affected. The projects were working on vaccines against bird flu and other viruses. "It will certainly make the U.S. poorer for not having a biotechnology industry that is not as competitive as it could be," added Hunter. "The U.S. will certainly lose out to China and Europe, and when its researchers move overseas, it may not be easy to get them to return later.""
Robert F. Kennedy Jr. is scrapping $500 million in funding for mRNA vaccine technology that was used to combat COVID-19. The U.S. Department of Health and Human Services said 22 projects by major pharmaceutical companies, including Pfizer and Moderna, will be affected; those projects were working on vaccines against bird flu and other viruses. Experts warn that other countries with active biotechnology industries, notably the U.K., China, and Europe, will benefit while U.S. competitiveness declines. Observers predict slower vaccine development, potential loss of lives, and migration of researchers overseas.
Read at Inside Higher Ed | Higher Education News, Events and Jobs
Unable to calculate read time
Collection
[
|
...
]